A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B

R. El Sharkawy, K. Thabet, P. Lampertico, S. Petta, A. Mangia, T. Berg, M. Metwally, A. Bayoumi, A. Boonstra, W.P. Brouwer, A. Smedile, M.L. Abate, A. Loglio, M.W. Douglas, A. Khan, R. Santoro, J. Fischer, D.J. Leeming, C. Liddle, J. GeorgeM. Eslam

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)564-573
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume48
Issue number5
DOIs
Publication statusPublished - 2018

Keywords

  • gamma interferon
  • interleukin 12
  • interleukin 18
  • STAT4 protein, adult
  • Article
  • Caucasian
  • chronic hepatitis B
  • controlled study
  • cytokine production
  • cytokine release
  • female
  • gene frequency
  • genetic association
  • genetic susceptibility
  • genetic variation
  • genotype
  • human
  • human cell
  • human tissue
  • liver fibrosis
  • liver tissue
  • lymphocyte function
  • major clinical study
  • male
  • natural killer cell
  • peripheral blood mononuclear cell
  • priority journal
  • protein analysis
  • protein expression
  • protein phosphorylation

Cite this

El Sharkawy, R., Thabet, K., Lampertico, P., Petta, S., Mangia, A., Berg, T., Metwally, M., Bayoumi, A., Boonstra, A., Brouwer, W. P., Smedile, A., Abate, M. L., Loglio, A., Douglas, M. W., Khan, A., Santoro, R., Fischer, J., Leeming, D. J., Liddle, C., ... Eslam, M. (2018). A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 48(5), 564-573. https://doi.org/10.1111/apt.14866